LIPITOR Drug Patent Profile
✉ Email this page to a colleague
When do Lipitor patents expire, and when can generic versions of Lipitor launch?
Lipitor is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lipitor
A generic version of LIPITOR was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIPITOR?
- What are the global sales for LIPITOR?
- What is Average Wholesale Price for LIPITOR?
Summary for LIPITOR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 228 |
Patent Applications: | 4,401 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LIPITOR |
Drug Sales Revenues: | Drug sales revenues for LIPITOR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LIPITOR |
What excipients (inactive ingredients) are in LIPITOR? | LIPITOR excipients list |
DailyMed Link: | LIPITOR at DailyMed |
![LIPITOR drug patent expirations Drug patent expirations by year for LIPITOR](/p/graph/s/t/LIPITOR-patent-expirations.png)
![Drug Prices for LIPITOR](/p/graph/drug-price/LIPITOR.png)
![Drug Sales Revenue Trends for LIPITOR](/p/graph/drug-sales-revenues/LIPITOR.png)
Recent Clinical Trials for LIPITOR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NYU Langone Health | Phase 4 |
Gannex Pharma Co., Ltd. | Phase 1 |
Montefiore Medical Center | N/A |
Pharmacology for LIPITOR
Drug Class | HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
US Patents and Regulatory Information for LIPITOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-002 | Dec 17, 1996 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LIPITOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-002 | Dec 17, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LIPITOR
See the table below for patents covering LIPITOR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Bulgaria | 63630 | ⤷ Sign Up | |
Australia | 601981 | ⤷ Sign Up | |
Poland | 193479 | ⤷ Sign Up | |
Philippines | 26330 | 7-(substituted-pyrrolyl)-3,5-di-hydroxyheptanoic acids | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LIPITOR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0247633 | C970034 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
0720599 | 92545 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910 |
1003503 | SZ 30/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN |
0247633 | 97C0103 | Belgium | ⤷ Sign Up | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |